JP7682553B2 - 癌の処置 - Google Patents

癌の処置 Download PDF

Info

Publication number
JP7682553B2
JP7682553B2 JP2022546059A JP2022546059A JP7682553B2 JP 7682553 B2 JP7682553 B2 JP 7682553B2 JP 2022546059 A JP2022546059 A JP 2022546059A JP 2022546059 A JP2022546059 A JP 2022546059A JP 7682553 B2 JP7682553 B2 JP 7682553B2
Authority
JP
Japan
Prior art keywords
nectin
antibody
cancer
optionally
linker
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2022546059A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023512036A (ja
JP2023512036A5 (https=
JPWO2021151984A5 (https=
Inventor
クライエム，マネル
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Innate Pharma SA
Original Assignee
Innate Pharma SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=74494891&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JP7682553(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Innate Pharma SA filed Critical Innate Pharma SA
Publication of JP2023512036A publication Critical patent/JP2023512036A/ja
Publication of JP2023512036A5 publication Critical patent/JP2023512036A5/ja
Publication of JPWO2021151984A5 publication Critical patent/JPWO2021151984A5/ja
Priority to JP2025077110A priority Critical patent/JP2025121970A/ja
Application granted granted Critical
Publication of JP7682553B2 publication Critical patent/JP7682553B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6889—Conjugates wherein the antibody being the modifying agent and wherein the linker, binder or spacer confers particular properties to the conjugates, e.g. peptidic enzyme-labile linkers or acid-labile linkers, providing for an acid-labile immuno conjugate wherein the drug may be released from its antibody conjugated part in an acidic, e.g. tumoural or environment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/68037—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a camptothecin [CPT] or derivatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Cell Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dermatology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2022546059A 2020-01-31 2021-01-28 癌の処置 Active JP7682553B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025077110A JP2025121970A (ja) 2020-01-31 2025-05-07 癌の処置

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202062968175P 2020-01-31 2020-01-31
US62/968,175 2020-01-31
PCT/EP2021/051938 WO2021151984A1 (en) 2020-01-31 2021-01-28 Treatment of cancer

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025077110A Division JP2025121970A (ja) 2020-01-31 2025-05-07 癌の処置

Publications (4)

Publication Number Publication Date
JP2023512036A JP2023512036A (ja) 2023-03-23
JP2023512036A5 JP2023512036A5 (https=) 2024-02-05
JPWO2021151984A5 JPWO2021151984A5 (https=) 2024-02-05
JP7682553B2 true JP7682553B2 (ja) 2025-05-26

Family

ID=74494891

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2022546059A Active JP7682553B2 (ja) 2020-01-31 2021-01-28 癌の処置
JP2025077110A Pending JP2025121970A (ja) 2020-01-31 2025-05-07 癌の処置

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025077110A Pending JP2025121970A (ja) 2020-01-31 2025-05-07 癌の処置

Country Status (9)

Country Link
US (1) US12594343B2 (https=)
EP (2) EP4512478A3 (https=)
JP (2) JP7682553B2 (https=)
CN (1) CN114845740A (https=)
AU (2) AU2021213421B2 (https=)
CA (1) CA3160557A1 (https=)
DK (1) DK4096717T3 (https=)
ES (1) ES3014740T3 (https=)
WO (1) WO2021151984A1 (https=)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022058395A1 (en) * 2020-09-15 2022-03-24 Synaffix B.V. Antibody-exatecan conjugates
CA3196198A1 (en) * 2020-11-25 2022-06-02 Manel KRAIEM Treatment of cancer
EP4086284A1 (en) * 2021-05-07 2022-11-09 Emergence Therapeutics AG Anti-nectin-4 antibody exatecan conjugates
CR20230470A (es) * 2021-03-31 2023-11-30 Univ Aix Marseille Conjugados de anticuerpo anti-nectina-4 y exatecano.
CN117500528A (zh) * 2021-06-18 2024-02-02 北京海步医药科技有限公司 连接子及其缀合物
CN118450907A (zh) * 2021-12-28 2024-08-06 百济神州有限公司 抗体药物结合物
EP4496593A1 (en) * 2022-03-23 2025-01-29 Synaffix B.V. Antibody-conjugates for targeting of tumours expressing nectin-4
KR20250009592A (ko) 2022-04-12 2025-01-17 미네르바 바이오테크놀로지 코포레이션 항-가변 muc1* 항체 및 그의 용도
CA3245954A1 (en) * 2022-05-25 2023-11-30 Innate Pharma NECTIN-4 LIAISON OFFICERS
EP4285935A1 (en) * 2022-06-03 2023-12-06 Emergence Therapeutics AG Novel anti-nectin-4 antibody camptothecin derivative conjugates
US20230408497A1 (en) * 2022-06-20 2023-12-21 Sysmex Corporation Labeled polypeptide, modified polypeptide, production method for these polypeptides, reagent containing these polypeptides, and measurement method for target substance
WO2024012541A1 (zh) * 2022-07-14 2024-01-18 百奥泰生物制药股份有限公司 抗Nectin-4抗体药物偶联物及应用
JP2025525518A (ja) * 2022-07-14 2025-08-05 バイオ－テラ ソリュ－ションズ，エルティーディー． 抗Ｎｅｃｔｉｎ－４抗体、その抗体薬物コンジュゲート及び応用
EP4309676A1 (en) * 2022-07-22 2024-01-24 Emergence Therapeutics AG Novel anti-nectin-4 antibody camptothecin derivative conjugates
WO2024028258A1 (en) * 2022-08-01 2024-02-08 Philochem Ag Conjugates of psma-binding moieties with cytotoxic agents
EP4324849A1 (en) * 2022-08-18 2024-02-21 Emergence Therapeutics AG Humanized anti-nectin-4 antibodies
EP4344707A1 (en) * 2022-09-29 2024-04-03 Emergence Therapeutics AG New anti-nectin-4 antibody drug conjugates
PE20252282A1 (es) * 2022-10-09 2025-09-18 Lanova Medicines Ltd Compuestos, composiciones y metodos
CN120417935A (zh) * 2022-10-25 2025-08-01 默沙东有限责任公司 依喜替康衍生的adc接头-载荷及其药物组合物和用途
IL320634A (en) * 2022-11-04 2025-07-01 Alx Oncology Inc EXATECAN derivatives and antibody-drug conjugates
AU2023377443A1 (en) * 2022-11-09 2025-05-08 Obi Pharma, Inc. Glycosynthase variants for antibody-drug conjugate engineering
WO2024191598A1 (en) * 2023-03-10 2024-09-19 Emory University Labeled amplifier oligonucleotides for detecting low or ultra low expression of cancer markers and uses in managing cancer treatments
CN118666946A (zh) * 2023-03-15 2024-09-20 上海亲合力生物医药科技股份有限公司 连接子及使用其的偶联药物、抗体偶联药物及其应用
CN118852442A (zh) 2023-04-26 2024-10-29 上海麦科思生物医药有限公司 抗ptk7抗体及其用途
EP4727971A1 (en) * 2023-06-13 2026-04-22 Adcentrx Therapeutics Inc. Methods and compositions related to antibodies and antibody drug conjugates (adcs) that bind nectin-4 proteins
JP7689606B2 (ja) * 2023-06-20 2025-06-06 イーライ リリー アンド カンパニー ネクチン－４抗体及び抗体－薬物コンジュゲート
WO2025003396A1 (en) * 2023-06-28 2025-01-02 Université De Tours Pegylated linkers and uses thereof
TW202530249A (zh) * 2023-09-29 2025-08-01 美商雅克提斯腫瘤學公司 小蛋白、結合物及其用途
EP4534102A1 (en) 2023-10-02 2025-04-09 Eli Lilly and Company Antibody drug conjugate (adc) targeting nectin 4 and comprising an exatecan payload
EP4534101A1 (en) 2023-10-02 2025-04-09 Eli Lilly and Company Antibody drug conjugate (adc) targeting nectin 4 and comprising an exatecan payload
WO2025078881A2 (en) * 2023-10-13 2025-04-17 Ligachem Biosciences Inc. Anti-claudin 18.2 antibody drug conjugates comprising topoisomerase i inhibitor and uses thereof
US20250121084A1 (en) * 2023-10-17 2025-04-17 Adc Therapeutics Sa Anti-claudin-6 conjugates
FR3155708A1 (fr) * 2023-11-27 2025-05-30 Skymab Biotherapeutics Conjugue anticorps-medicament et ses utilisations
FR3155709A1 (fr) * 2023-11-27 2025-05-30 Skymab Biotherapeutics Conjugue anticorps-medicament et ses utilisations
AU2024394903A1 (en) * 2023-12-06 2026-04-02 Adc Therapeutics Sa Anti-psma antibody drug conjugates comprising exatecan
WO2025153092A1 (en) * 2024-01-18 2025-07-24 Beijing Joinn Biologics Co., Ltd Antibody-drug conjugate
WO2025209545A1 (zh) * 2024-04-03 2025-10-09 上海药明合联生物技术有限公司 用于抗体药物偶联物的连接子、其用途和由其制备的抗体药物偶联物
FR3164899A1 (fr) * 2024-07-24 2026-01-30 Skymab Biotherapeutics Conjugue anticorps-medicament et ses utilisations

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US6673986B1 (en) 1990-01-12 2004-01-06 Abgenix, Inc. Generation of xenogeneic antibodies
US5776427A (en) 1992-03-05 1998-07-07 Board Of Regents, The University Of Texas System Methods for targeting the vasculature of solid tumors
US6214345B1 (en) 1993-05-14 2001-04-10 Bristol-Myers Squibb Co. Lysosomal enzyme-cleavable antitumor drug conjugates
HK1040052B (zh) * 1998-05-22 2006-09-15 第一制药株式会社 药物复合物
EP1243276A1 (en) 2001-03-23 2002-09-25 Franciscus Marinus Hendrikus De Groot Elongated and multiple spacers containing activatible prodrugs
AU2003240482B2 (en) 2002-05-30 2009-03-12 The Scripps Research Institute Copper-catalysed ligation of azides and acetylenes
JP2006507322A (ja) 2002-11-14 2006-03-02 シンタルガ・ビーブイ 多重自己脱離放出スペーサーとして構築されたプロドラッグ
EP1718667B1 (en) 2004-02-23 2013-01-09 Genentech, Inc. Heterocyclic self-immolative linkers and conjugates
DK1812031T3 (en) 2004-11-01 2015-09-14 Univ California Compositions and methods for the modification of biomolecules
CN104529711B (zh) 2007-11-21 2020-02-07 乔治亚大学研究基金公司 炔烃以及炔烃与1,3-偶极-官能化合物反应的方法
US20110301056A1 (en) 2008-12-12 2011-12-08 Oncotherapy Science, Inc. Nectin-4 for target genes of cancer therapy and diagnosis
US20130005678A1 (en) 2010-03-30 2013-01-03 Clavis Pharma Asa Methods and Compositions for Treating or Ameliorating Cancer Using Gemcitabine-5'-Elaidate
EP3409287B9 (en) 2010-09-29 2021-07-21 Agensys, Inc. Antibody drug conjugates (adc) that bind to 191p4d12 proteins
US9764038B2 (en) 2011-12-23 2017-09-19 Innate Pharma Enzymatic conjugation of antibodies
EP3010547B1 (en) 2013-06-20 2021-04-21 Innate Pharma Enzymatic conjugation of polypeptides
ES2826398T3 (es) 2013-10-15 2021-05-18 Seagen Inc Enlazadores-fármacos pegilados para una mejor farmacocinética de los conjugados ligando-fármaco
WO2016053107A1 (en) 2014-10-03 2016-04-07 Synaffix B.V. Sulfamide linker, conjugates thereof, and methods of preparation
ES2885854T3 (es) 2014-10-14 2021-12-15 Polytherics Ltd Proceso para la conjugación de un péptido o proteína con un reactivo que comprende un grupo saliente que incluye una porción de PEG
US10675357B2 (en) 2015-09-09 2020-06-09 INSERM (Institut National de la Santé et de la Recherche Médicale Antibodies having specificity to nectin-4 and uses thereof
ES2921236T3 (es) 2016-11-25 2022-08-22 Mabwell Shanghai Bioscience Co Ltd Enlazador de amida maleica disustituida para la conjugación de anticuerpo y fármaco y método de preparación y uso del mismo
US11274160B2 (en) 2017-03-02 2022-03-15 INSERM (Institut National de la Santé et de la Recherche Médicale Antibodies having specificity to Nectin-4 and uses thereof
CN111675761B (zh) 2017-06-05 2023-10-20 艾更斯司股份有限公司 柄蛋白-4结合蛋白及其使用方法
JP7551056B2 (ja) 2017-10-05 2024-09-17 ソニーグループ株式会社 プログラマブルなポリマー薬物
JP7381478B2 (ja) * 2017-10-23 2023-11-15 マブリンク ビオシオンス 単一分子量ポリサルコシンを含むリガンド－薬物－複合体
TWI851577B (zh) 2018-06-07 2024-08-11 美商思進公司 喜樹鹼結合物
WO2020063676A1 (zh) 2018-09-26 2020-04-02 江苏恒瑞医药股份有限公司 依喜替康类似物的配体-药物偶联物及其制备方法和应用
CN112543771B (zh) 2018-09-30 2023-04-11 江苏豪森药业集团有限公司 抗b7h3抗体-依喜替康类似物偶联物及其医药用途
JP7629902B2 (ja) 2019-03-19 2025-02-14 パウル・シェラー・インスティトゥート グリシンベースリンカーを用いたトランスグルタミナーゼコンジュゲーション法
JP7561141B2 (ja) * 2019-04-26 2024-10-03 イミュノジェン・インコーポレーテッド カンプトテシン誘導体
JP7167163B2 (ja) 2019-05-20 2022-11-08 煙台邁百瑞国際生物医薬股▲ふん▼有限公司 抗体－薬物コンジュゲートの中間体のワンポット合成法による製造プロセス
JP2022551537A (ja) 2019-10-07 2022-12-09 ユニヴェルシテ デクス－マルセイユ ネクチン－４に対する特異性を有する抗体及びその使用
CA3162282A1 (en) 2019-11-25 2021-06-03 Agensys, Inc. Treatment of cancers with antibody drug conjugates (adc) that bind to 191p4d12 proteins
CN113527486B (zh) 2020-04-21 2025-12-02 迈威(上海)生物科技股份有限公司 一种抗Nectin-4的抗体及其应用
CA3182395A1 (en) 2020-06-18 2021-12-23 Jay M. Short Conditionally active anti-nectin-4 antibodies
US20230331867A1 (en) 2020-09-04 2023-10-19 Novarock Biotherapeutics, Ltd. Nectin-4 antibodies and uses thereof
WO2022058395A1 (en) 2020-09-15 2022-03-24 Synaffix B.V. Antibody-exatecan conjugates
CA3196198A1 (en) 2020-11-25 2022-06-02 Manel KRAIEM Treatment of cancer
CA3245954A1 (en) 2022-05-25 2023-11-30 Innate Pharma NECTIN-4 LIAISON OFFICERS

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Cancer Research，2016年，Vol.76，No.10，p.3003-3013

Also Published As

Publication number Publication date
US20230099149A1 (en) 2023-03-30
WO2021151984A1 (en) 2021-08-05
JP2023512036A (ja) 2023-03-23
DK4096717T3 (da) 2025-03-03
CN114845740A (zh) 2022-08-02
AU2025202617A1 (en) 2025-05-15
AU2021213421A1 (en) 2022-06-23
EP4512478A3 (en) 2025-05-21
EP4512478A2 (en) 2025-02-26
JP2025121970A (ja) 2025-08-20
CA3160557A1 (en) 2021-08-05
EP4096717B1 (en) 2024-12-11
US12594343B2 (en) 2026-04-07
EP4096717A1 (en) 2022-12-07
AU2021213421B2 (en) 2025-02-06
ES3014740T3 (en) 2025-04-24

Similar Documents

Publication Publication Date Title
JP7682553B2 (ja) 癌の処置
KR20230112656A (ko) 암의 치료
US12365731B2 (en) NKp46 binding agents
CN111212853A (zh) 可活化的抗cd166抗体及其使用方法
JP2025517476A (ja) ネクチン－４結合剤
JP2016528183A (ja) ポリペプチドの酵素的結合
RU2750817C1 (ru) Применение конъюгата анти-her2 антитело-лекарственное средство при лечении уротелиальной карциномы
CN116685342A (zh) 癌症的治疗

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240126

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20240126

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20240502

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250204

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20250206

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250307

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20250408

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20250507

R150 Certificate of patent or registration of utility model

Ref document number: 7682553

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150